Cegolon, L.; Pol, R.; Simonetti, O.; Larese Filon, F.; Luzzati, R.
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals 2023, 16, 721.
https://doi.org/10.3390/ph16050721
AMA Style
Cegolon L, Pol R, Simonetti O, Larese Filon F, Luzzati R.
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals. 2023; 16(5):721.
https://doi.org/10.3390/ph16050721
Chicago/Turabian Style
Cegolon, Luca, Riccardo Pol, Omar Simonetti, Francesca Larese Filon, and Roberto Luzzati.
2023. "Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life" Pharmaceuticals 16, no. 5: 721.
https://doi.org/10.3390/ph16050721
APA Style
Cegolon, L., Pol, R., Simonetti, O., Larese Filon, F., & Luzzati, R.
(2023). Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals, 16(5), 721.
https://doi.org/10.3390/ph16050721